BTM

BTM Therapeutics is a clinical-stage biotechnology company pioneering the development of a novel class of small molecule therapeutics targeting mitochondrial biology for the treatment of cancer. The company's lead candidate, BTM-3566, is a first-in-class inhibitor of mitochondrial translation that has demonstrated potent activity in preclinical models of B-cell malignancies. Currently in Phase 1 clinical development, BTM-3566 aims to address significant unmet needs in patients with relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma. BTM's approach leverages the unique dependency of certain cancer cells on mitochondrial protein synthesis to induce selective apoptosis. The company continues to explore the potential of its platform in other hematologic and solid tumor indications.